Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: Toll-like receptors (TLRs) have been implicated in the pathogenesis of glioma as principal regulators of inflammation and innate immune function. Considering the heterogeneous nature of gliomas, ranging from low to high grade with different therapeutic responses, investigating the differences in the levels of TLR2 and TLR4 and associated inflammatory markers in these distinct groups is of great clinical significance.

Materials And Methods: In this study, we investigated changes in the protein expression levels of TLR2 and TLR4, along with key inflammatory mediators, including nuclear factor kappa B (NF-κB) as a downstream signaling molecule, and tumor necrosis factor-alpha (TNF-α), a target of NF-κB activation, by using western blotting. Primary human cells were isolated from surgically resected tissue samples of patients with low- and high-grade gliomas and were compared to cells derived from the human epileptic brain. cell characterization was performed via immunocytochemistry using markers specific to each group.

Results: Protein levels were assessed by western blotting. TLR2 expression was significantly higher in the high-grade glioma group compared to the low-grade group. The expression of TLR2 and TLR4 was significantly greater in the epilepsy group compared to the low-grade glioma group. No remarkable differences were detected in the levels of NF-κB and TNF-α between high and low-grade gliomas.

Conclusion: Our results revealed distinct patterns of TLR expression between low- and high-grade gliomas, underscoring the potential involvement of TLRs in the cellular heterogeneity of gliomas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340408PMC
http://dx.doi.org/10.22038/ijbms.2025.83939.18166DOI Listing

Publication Analysis

Top Keywords

low- high-grade
12
tlr2 tlr4
12
toll-like receptors
8
inflammatory mediators
8
primary human
8
levels tlr2
8
western blotting
8
high-grade gliomas
8
glioma group
8
group compared
8

Similar Publications

Evaluation of tumor infiltrating lymphocytes as recommended by current guidelines is largely based on stromal regions within the tumor. In the context of epithelial malignancies, the epithelial region and the epithelial-stromal interface are not assessed, because of technical difficulties in manually discerning lymphocytes when admixed with epithelial tumor cells. The inability to quantify immune cells in epithelial-associated areas may negatively impact evaluation of patient response to immune checkpoint therapies.

View Article and Find Full Text PDF

Purpose: Amino acid PET with [F]-fluoroethylthyrosine ([F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors with low- and high-grade features. The objective of this study was to assess the potential prognostic value of [F]FET-PET-based markers in the group of grade 2 adult-type diffuse gliomas, as defined by the WHO CNS 2021 classification.

View Article and Find Full Text PDF

Introduction: The optimal surveillance for mucinous appendix cancer (MAC) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) remains unclear. We identified postoperative periods reflecting significant changes in recurrence probability.

Methods: A prospective database (1998-2024) of patients with stage IV MAC with low-grade (LGMCP), high-grade (HGMCP), and signet-ring cell (SRC) histology treated with initial complete (CC-0/1) CRS/HIPEC was analyzed.

View Article and Find Full Text PDF

Background: Anal squamous cell cancer incidence has risen 2.2% each year over the past decade. Current screening includes anal cytology and high-resolution anoscopy but is burdened with sampling error and patient discomfort.

View Article and Find Full Text PDF

Amivantamab, a bispecific EGFR-MET antibody, has demonstrated efficacy in EGFR-mutant non-small cell lung cancer (NSCLC) across multiple trials and is poised to enter first-line therapy. However, as with EGFR-targeted therapies, amivantamab is associated with distinctive cutaneous toxicities. This perspective summarizes clinical evidence on the frequency, nature, and severity of skin-related adverse events from key studies, outlining how, despite concerns initially raised among clinicians about its tolerability in routine practice, clinical experience indicates that amivantamab's cutaneous toxicities are manageable with proactive strategies and education.

View Article and Find Full Text PDF